Japanese MHLW approves Cresemba for aspergillosis, mucormycosis, and cryptococcosis.- Basilea Pharmaceutica
Basilea Pharmaceutica announced that its license partner Asahi Kasei Pharma, has received the marketing authorization from the Ministry of Health, Labour and Welfare (MHLW) in Japan for Cresemba (isavuconazole) for the treatment of adult patients with aspergillosis, mucormycosis, and cryptococcosis. Aspergillosis and cryptococcosis were recently listed by the World Health Organization as most critical fungal infections that pose a major health risk.
In China, the oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the United States and several additional countries in Europe and beyond. It has orphan drug designation in the U.S. Europe and Australia for its approved indications.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.